PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated,…
By L. Schwartzberg, F. Rivera, M. Karthaus, G. Fasola, J. Canon, J. Hecht, Hua Yu, K. Oliner, W. Go. Journal of Clinical Oncology, 2014
634 citations recorded by the source corpus.
Subfields: Biotechnology, Oncology
View Paper: https://www.semanticscholar.org/paper/fcdfe33937ba3bb38ab622ed6c880d91c2b4f7e7
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “89) 4* [103]”
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, result): “The same pattern [OS benefit in the RAS cohort (retrospective analysis, secondary endpoint) without difference in OS and PFS (primary endpoint)] was observed in a smaller phase II study comparing FOLFOX with panitumumab or bevacizumab [48].”
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, methodology): “Patients with KRAS and NRAS exon 2, 3 and 4 wild-type mCRC treated with FOLFOX6 plus panitumumab achieved a better PFS than those treated with FOLFOX6 plus bevacizumab and a trend towards improved OS was also observed [53].”
- Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † (2017, methodology): “Methods The present pooled analyses are based on data from the randomized CRYSTAL (NCT00154102) [33], PRIME (NCT00364013) [34], PEAK (NCT00819780) [35], FIRE-3 (NCT00433927) [36, 37], 1714 | Arnold et al. Volume 28 | Issue 8 | 2017 Downloaded from https://academic.oup.com/annonc/article-abstract/28/”
- Controversies in colorectal cancer: First line treatment with epidermal growth factor inhibitors and RAS in 2014 (2014, result): “Two of these clinical trials, FIRE 3[10] and PEAK,[11] but not yet Cancer and Leukemia Group B (CALGB) 80405,[12] also corroborated the results of extended RAS testing.”